Last reviewed · How we verify
Gemcitabine and cisplatin / carboplatin
Gemcitabine and cisplatin / carboplatin is a Chemotherapy combination (nucleoside analog + platinum agent) Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer, Urothelial carcinoma, Ovarian cancer.
Gemcitabine and cisplatin/carboplatin is a chemotherapy combination that damages cancer cell DNA through complementary mechanisms to inhibit tumor growth.
Gemcitabine and cisplatin/carboplatin is a chemotherapy combination that damages cancer cell DNA through complementary mechanisms to inhibit tumor growth. Used for Advanced or metastatic non-small cell lung cancer, Urothelial carcinoma, Ovarian cancer.
At a glance
| Generic name | Gemcitabine and cisplatin / carboplatin |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. Cisplatin and carboplatin are platinum-based alkylating agents that form DNA cross-links, preventing replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Urothelial carcinoma
- Ovarian cancer
- Pancreatic cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Peripheral neuropathy
- Fatigue
- Alopecia
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine and cisplatin / carboplatin CI brief — competitive landscape report
- Gemcitabine and cisplatin / carboplatin updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about Gemcitabine and cisplatin / carboplatin
What is Gemcitabine and cisplatin / carboplatin?
How does Gemcitabine and cisplatin / carboplatin work?
What is Gemcitabine and cisplatin / carboplatin used for?
Who makes Gemcitabine and cisplatin / carboplatin?
What drug class is Gemcitabine and cisplatin / carboplatin in?
What development phase is Gemcitabine and cisplatin / carboplatin in?
What are the side effects of Gemcitabine and cisplatin / carboplatin?
Related
- Drug class: All Chemotherapy combination (nucleoside analog + platinum agent) drugs
- Manufacturer: Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer
- Indication: Drugs for Urothelial carcinoma
- Indication: Drugs for Ovarian cancer
- Compare: Gemcitabine and cisplatin / carboplatin vs similar drugs
- Pricing: Gemcitabine and cisplatin / carboplatin cost, discount & access